Maintenance therapy for first-line metastatic colorectal cancer: Activity and sustainability

Oncologist

Volumn 17, Issue 1, 2012, Pages 9-10

  Strickler, John H ^a   Hurwitz, Herbert I ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; COLORECTAL CANCER; DIARRHEA; HUMAN; MAINTENANCE THERAPY; METASTASIS; MONOTHERAPY; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE;

EID: 84856264430     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0358     Document Type: Article

References (6)

1. Díaz-Rubio E, Gómez-España A, Massutí B et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. The Oncologist 2012;17:15-25.
2. Chibaudel B, Maindrault-Goebel F, Lledo G et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009;27:5727-5733.
3. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006;24:394-400.
4. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25: 1539-1544.
5. ClinicalTrials. gov. Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma (CAIRO3). ClinicalTrials. gov Identifier, NCT00442637. Available at http:// clinicaltrials.gov/ct2/show/NCT00442637?term_ NCT00442637&rank_1, accessed October 7, 2011.
6. Tournigand C, Scheithauer BSW, Andre CLT et al. mFOLFOX-bevacizumab or XELOX-bevacizumab then bevacizumab (B) alone or with erlotinib (E) in first-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety analysis of DREAM study. J Clin Oncol 2009;27(15 suppl):Abstract 4077.